Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Blumberg

Allergy & Immunology Richmond, VA Medical Doctor

NPI 1093792517 CMS profile 322164

7605 Forest Ave, Suite 103, Richmond, VA 23229

Open in the dashboard

General payments

$32,248

468 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Blumberg of Richmond, VA is reported in the CMS Open Payments database as having received $32,248 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2024 General $17 1
2023 General $3,165 82
2022 General $6,867 107
2021 General $11,251 103
2020 General $6,209 88
2019 General $4,725 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Blumberg
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Michael Blumberg were reported at $15. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Michael Blumberg Allergy & Immunology median Middle half National median
2019 $4,725 $594 $163–$1,512 $163
2020 $6,209 $426 $106–$1,233 $114
2021 $11,251 $638 $157–$1,708 $132
2022 $6,867 $790 $205–$1,961 $149
2023 $3,165 $852 $220–$2,147 $160
2024 $17 $865 $203–$2,267 $164
2025 $15 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $22,383 125 payments
  2. OptiNose US, Inc. $4,048 59 payments
  3. AstraZeneca Pharmaceuticals LP $1,522 65 payments
  4. Regeneron Healthcare Solutions, Inc. $897 36 payments
  5. Genzyme Corporation $443 21 payments
  6. Genentech USA, Inc. $362 26 payments
  7. kaleo, Inc. $334 19 payments
  8. CSL Behring $261 14 payments
  9. Novartis Pharmaceuticals Corporation $232 14 payments
  10. Pfizer Inc. $221 15 payments
  11. Other $1,545 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,900 12 payments
  2. Food and Beverage $8,086 448 payments
  3. Consulting Fee $2,500 1 payment
  4. Travel and Lodging $562 3 payments
  5. Education $200 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $20,289 67 payments
  2. Xhance $4,048 59 payments
  3. DUPIXENT Immunology $1,002 44 payments
  4. DUPIXENT Inflammation And Immunology $926 37 payments
  5. FASENRA Respiratory $625 24 payments
  6. NUCALA Immunology $427 30 payments
  7. FASENRA Respiratory $372 12 payments
  8. Xolair $362 26 payments
  9. NUCALA Respiratory $347 25 payments
  10. AUVI-Q $334 19 payments
  11. Other $3,000 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

173

Median for Allergy/ Immunology: 449

Drug cost

$90,822

Median for Allergy/ Immunology: $169,700

Branded share of claims

45.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 42 $42,843
Dupixent Pen Dupilumab Brand 11 $39,555
Breo Ellipta Fluticasone/Vilanterol Brand 11 $5,189
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 15 $1,696
Azelastine Hcl Generic 32 $640
Fluticasone Propionate Generic 35 $588
Montelukast Sodium Generic 15 $201
Azithromycin Generic 12 $111

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Hizentra
  • CSL Behring $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record